CN
  • Renewed co-development collaboration with Calibr on the development of AK0705
    2023
  • Initiated AK3280's phase 2 study in China

    Initiated AK3287's phase 1/2 study

    Ziresovir's phase 3 study completed, primary endpoint & key secondary endpoints met

    Completed series D round of fundraising

    AK0529's NDA has been accepted and granted Priority Review by NMPA
    2022
  • Completed series C round of fundraising

    Initiated ziresovir's phase 1 study in the US

    In-licensed FDA-approved ADHD treatment AZSTARYS from Commave
    2021
  • First-time presentation at J.P. Morgan Healthcare Conference

    Initiated ziresovir's phase 3 study

    Out-licensed AK0706's China rights to Amoytop

    Ziresovir received breakthrough designation by NMPA

    Awarded gold medal in innovation competition by National Health Commission of China for the development of ziresovir
    2020
  • Initiated AK3280 phase 1b study in Sweden
    2019
  • Completed series B round of fundraising

    In-licensed AK3280 global rights from Genentech/Intermune/Roche
    2018
  • Completed series A+ round of fundraising

    Completed ziresovir's Chinese phase 1 study and first Chinese adult dosing

    Started collaboration with Calibr on the development of AK0705
    2017
  • Established Suzhou R&D Center
    2016
  • Completed series A round of fundraising
    2015
  • Ark Biopharmaceutical founded

    In-licensed ziresovir global rights from Roche

    Initiated ziresovir's phase 1 study in Australia and completed FIH dosing

    Completed angel round of fundraising
    2014
  • Ark Biosciences Inc. founded
    2013
Expand
MORE
TOP

About Us

Research

Pipeline

Media

Career

Contact Us

Investor Relations

Telephone：
+86 21 50681677
Address：
Building 25, Lane 388, Shengrong Road, Pudong, Shanghai 201203, China
E-mail：
ir@arkbiosciences.com
Official Account
  • Home
  • Tel
  • Top